



Alliance for Clinical Trials in Oncology

Date Thursday, November 7, 2019

Loews Chicago O'Hare Hotel

Time 5:00 –7:00 pm

Radiation Oncology Committee Meeting Agenda

Chair: Jeff Bogart

Vice-Chair: Joseph Salama

PRESENTATION

CALGB 30610 : COMPARISON OF TOXICITY ON EXPERIMENTAL ARMS (ESMO, BOGART)

PRIORITY DISCUSSION

- PHASE I/II TRIAL OF FIVE FRACTION FSRT FOR LARGE BRAIN METASTASES (MELLON)
- SRS FOR SMALL CELL BRAIN METASTASES (SCHILD)
- AFT-46 NEOADJUVANT CHEMOTHERAPY/ IO FOR SURGICAL STAGE III NSCLC (URBANIC)

ACTIVE/RECENTLY COMPLETED STUDIES

CNS

- o CE.7 SRS vs WBRT for Multiple Brain Metastases
- o NRG-BN003 - Phase III trial of observation versus irradiation for a gross totally resected grade II meningioma
- o NRG-BN005 - A Phase II Randomized Trial of Proton vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients with IDH Mutant, Low to Intermediate Grade Gliomas
- A071601 - Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

Lung

- o AFT- 16: Induction PDL-1 inhibition Stage III NSCLC *Urbanic*
- o NRG CC003: PCI with or without Hippocampal Avoidance for SCLC *Grecula*

- Lu-002 Phase III Immunotherapy for Limited Stage SCLC

Breast

- Alliance A221505 Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction (**RT CHARM**) Poppe
- A011202 A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy
- NRG Oligometastatic Trials *Salama/Mohindra*

GI

- GI Study Update (Mamon)

GU

- **A031701** PHASE II STUDY OF DOSE-DENSE GEMCITABINE PLUS CISPLATIN (DDGC) IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WITH BLADDER PRESERVATION FOR THOSE PATIENTS WHOSE TUMORS HARBOR DELETERIOUS DNA DAMAGE RESPONSE (DDR) GENE ALTERATIONS (KWOK)
- PROSTATE CANCER STUDIES (CHEN)

IROC Update